New Drug Approvals. New Drug Approvals 173. Amlodipine and Celecoxib (Tablets - formerly KIT-302) Company: Kitov Pharma Ltd.
|
|
- Morris Jacobs
- 5 years ago
- Views:
Transcription
1 New Drug Approvals 173 New Drug Approvals Cannabidiol (Oral Solution) Company: GW Pharmaceuticals plc Date of Approval: June 25, 2018 Epidiolex (cannabidiol) is a prescription pharmaceutical formulation of highly-purified, marijuana plant-derived cannabidiol (CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age or older. Desmopressin Acetate (Sublingual Tablets) Company: Ferring Pharmaceuticals Inc. Date of Approval: June 21, 2018 Nocdurna (desmopressin acetate) is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults. Moxidectin Tablets Company: Medicines Development for Global Health Date of Approval: June 13, 2018 Moxidectin is a macrocyclic lactone anthelmintic medicine indicated for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older. Pegfilgrastim-jmdb (Injection) Company: Mylan N.V. Date of Approval: June 4, 2018 Fulphila (pegfilgrastim-jmbd) is a leukocyte growth factor biosimilar to Neulasta (pegfilgrastim) indicated to reduce the duration of febrile neutropenia in patients treated with chemotherapy. Baricitinib (Tablets) Company: Eli Lilly and Company Date of Approval: May 31, 2018 Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. Amlodipine and Celecoxib (Tablets - formerly KIT-302) Company: Kitov Pharma Ltd. Date of Approval: May 31, 2018 Consensi (amlodipine and celecoxib) is a calcium channel blocker and nonsteroidal anti-inflammatory drug combination for the treatment of both hypertension and pain associated with osteoarthritis. Estradiol (Vaginal Inserts) Company: TherapeuticsMD, Inc. Date of Approval: May 29, 2018 Imvexxy (estradiol) is a bio-identical 17β-estradiol vaginal insert for the treatment of dyspareunia (vaginal pain during sexual intercourse) due to menopause. Pegvaliase-pqpz (Injection) Company: BioMarin Pharmaceutical Inc. Date of Approval: May 24, 2018 Palynziq (pegvaliase-pqpz) is a phenylalaninemetabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria. Abiraterone Acetate (Tablets) Company: Sun Pharmaceutical Industries Inc. Date of Approval: May 22, 2018 Yonsa (abiraterone acetate) is an ultramicrosize formulation of the oral CYP17 inhibitor abiraterone acetate (approved as Zytiga) used in combination with methylprednisolone for the treatment of metastatic castration-resistant prostate cancer. Avatrombopag (Tablets) Company: Dova Pharmaceuticals, Inc. Date of Approval: May 21, 2018 Doptelet (avatrombopag) is a second generation, orally administered thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of thrombocytopenia in patients with chronic liver
2 174 New Drug Approvals disease who are scheduled to undergo a medical procedure. Sodium Zirconium Cyclosilicate (Oral Suspension) Company: AstraZeneca Date of Approval: May 18, 2018 Lokelma (sodium zirconium cyclosilicate) is a potassium binder indicated for the treatment of hyperkalemia in adults. Erenumab-Aooe (Injection) Company: Amgen Inc. Date of Approval: May 17, 2018 Aimovig (erenumab-aooe) is a calcitonin generelated peptide (CGRP) receptor antagonist indicated for the preventive treatment of migraine. lofexidine Hydrochloride (Tablets) Company: US WorldMeds Date of Approval: May 16, 2018 Lucemyra (lofexidine hydrochloride) is a selective 2-adrenergic receptor agonist indicated for reducing the severity of withdrawal symptoms in patients experiencing opioid withdrawal. Epoetin Alfa-Epbx (Injection) Company: Hospira, Inc. Date of Approval: May 15, 2018 Retacrit (epoetin alfa-epbx) is an erythropoiesisstimulating agent (ESA) biosimilar to Epogen/Procrit (epoetin alfa) indicated for treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery. Polyethylene glycol 3350 with electrolytes (Oral Solution) Company: Salix Pharmaceuticals, Inc. Date of Approval: May 4, 2018 Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride) is a lower-volume, polyethylene glycol based osmotic laxative indicated for cleansing of the colon (bowel preparation) prior to colonoscopy. Coagulation factor Xa (recombinant), inactivatedzhzo Company: Portola Pharmaceuticals, Inc. Date of Approval: May 3, 2018 Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a recombinant modified human Factor Xa (FXa) protein indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Tolvaptan (Tablets) Company: Otsuka Pharmaceutical Co., Ltd Date of Approval: April 23, 2018 Jynarque (tolvaptan) is a selective vasopressin V 2 - receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Fosnetupitant and palonosetron Company: Helsinn Healthcare SA Date of Approval: April 19, 2018 Akynzeo for Injection (fosnetupitant and palonosetron) is a substance P/neurokinin-1 (NK-1) receptor antagonist and serotonin-3 (5-HT3) receptor antagonist combination indicated for use with dexamethasone for the prevention of chemotherapyinduced nausea and vomiting (CINV). Burosumab-twza (Injection) Company: Ultragenyx Pharmaceutical Inc. Date of Approval: April 17, 2018 Crysvita (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody for the treatment of x-linked hypophosphatemia (XLH).
3 New Drug Approvals 175 Fostamatinib (Tablets) Company: Rigel Pharmaceuticals, Inc. Date of Approval: April 17, 2018 Tavalisse (fostamatinib) is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of patients with chronic immune thrombocytopenia (ITP). Ibalizumab-uiyk (Injection) Date of Approval: March 6, 2018 Company: TaiMed Biologics USA Corp. Trogarzo (ibalizumab-uiyk) is a CD4-directed postattachment HIV-1 inhibitor for the treatment of multidrug resistant human immunodeficiency virus-1 (HIV-1) infection in heavily treatment-experienced adults. Efavirenz, lamivudine and tenofovir disoproxil fumarate (Tablets) Date of Approval: March 22, 2018 Company: Mylan N.V. Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor (efavirenz), and two nucleo(t)side reverse transcriptase inhibitors (lamivudine and tenofovir disoproxil fumarate) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Source: Drugs.com Tildrakizumab-asmn (Injection) Date of Approval: March 20, 2018 Company: Sun Pharmaceutical Industries Ltd. Ilumya (tildrakizumab-asmn) is a humanized, anti- IL-23p19 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis. Information Collected and complied by: Md. Akbar Hossain Department of Pharmacy ASA University Bangladesh
4 176 New indications & dosage form New for Drug existing Approvals drugs New Indications & Dosage form for Existing Drugs Immune globulin subcutaneous FDA approves Hizentra (Immune Globulin subcutaneous [Human] 20% Liquid) for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) New Indication Approved: March 15, 2018 Brentuximab vedotin FDA expands approval of adcetris (brentuximab vedotin) for first-line treatment of stage III or IV classical hodgkin lymphoma in combination with chemotherapy. New Indication Approved: March 20, 2018 Bevacizumab (Injection) Avastin (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody for the treatment of colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, fallopian tube cancer, and peritoneal cancer. New Indication Approved: June 13, 2018 Pembrolizumab (Injection) Keytruda (pembrolizumab) is a human PD-1 (programmed death receptor-1)-blocking antibody indicated for the treatment of melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, cervical cancer, and primary mediastinal large B-cell lymphoma. New Indication Approved: June 13, 2018 Pembrolizumab (Injection) Keytruda (pembrolizumab) is a human PD-1 (programmed death receptor-1)-blocking antibody indicated for the treatment of melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, cervical cancer, and primary mediastinal large B-cell lymphoma. New Indication Approved: June 12, 2018 Venetoclax (Tablets) Venclexta (venetoclax) is an oral B-cell lymphoma-2 (BCL-2) inhibitor for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion. New Indication Approved: June 8, 2018 Rituximab (Injection for Intravenous Use) Rituxan (rituximab) is a CD20-directed cytolytic antibody indicated for the treatment of patients with non-hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, Wegener's granulomatosus, microscopic polyangiitis, and pemphigus vulgaris. New Indication Approved: June 7, 2018 Tofacitinib (Tablets) Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis. New Indication Approved: May 30, 2018 Certolizumab pegol (Injection) Cimzia (certolizumab) is a PEGylated anti-tnf (tumor necrosis factor) biologic therapy for the treatment of Crohn s disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. New Indication Approved: May 25, 2018 Denosumab (Injection) Prolia is a RANK ligand (RANKL) inhibitor indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, for the treatment of bone loss in patients with prostate or breast cancer undergoing hormone ablation therapy, as a treatment to increase bone mass in men with osteoporosis at high risk for fracture, and for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture. New Indication Approved: May 18, 2018
5 New Drug indications Approvals & dosage form for existing drugs 177 Ixekizumab (Injection) Taltz (ixekizumab) is a humanized interleukin-17a antagonist indicated for the treatment of plaque psoriasis and psoriatic arthritis. New Indication Approved: May 17, 2018 Tocilizumab (Injection) Actemra (tocilizumab) is a humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody for the treatment of rheumatoid arthritis; systemic juvenile idiopathic arthritis (SJIA); polyarticular juvenile idiopathic arthritis (PJIA); giant cell arteritis; and CAR T cell-induced severe or life-threatening cytokine release syndrome. New Dosage Regimen: May 11, 2018 Daratumumab (Injection) Darzalex (daratumumab) is a human anti-cd38 monoclonal antibody indicated for the treatment of patients with multiple myeloma. New Indication Approved: May 7, 2018 Tisagenlecleucel (Suspension for Intravenous Infusion) Kymriah (tisagenlecleucel) is a chimeric antigen receptor T cell (CAR-T) therapy for use in patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) and patients with relapsed or refractory (r/r) large B-cell lymphoma. New Indication Approved: May 1, 2018 Mirabegron (Extended Release Tablets) Myrbetriq (mirabegron) is a -3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. New Indication Approved: April 27, 2018 Osimertinib (Tablets) Tagrisso (osimertinib) is a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) indicated for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer. New Indication Approved: April 18, 2018 Nivolumab (Injection) Opdivo (nivolumab) is a programmed death receptor- 1 (PD-1) blocking antibody for the treatment of advanced melanoma, advanced non-small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, advanced squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H or dmmr metastatic colorectal cancer and hepatocellular carcinoma. New Indication Approved: April 16, 2018 Everolimus (Tablets) Afinitor (everolimus) is an oral once-daily inhibitor of mtor indicated for the treatment of patients with advanced HR+, HER2- breast cancer; progressive neuroendocrine tumors of pancreatic origin (PNET); progressive neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin; advanced renal cell carcinoma; and subependymal giant cell astrocytoma (SEGA) and renal angiomyolipomas associated with tuberous sclerosis. New Indication Approved: April 10, 2018 Rucaparib (Tablets) Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies; and for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. New Indication Approved: April 6, 2018 Bupivacaine liposome (Injectable Suspension) Exparel (bupivacaine liposome injectable suspension) is a long-acting non-opioid local analgesic for postsurgical local analgesia, and for use as a nerve block (interscalene brachial plexus block) to provide pain relief following shoulder surgeries. New Indication Approved: April 6, 2018
6 178 New indications & dosage form New for Drug existing Approvals drugs Blinatumomab (Injection) Blincyto (blinatumomab) is a bispecific CD19- directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and minimal residual disease (MRD)-positive B-cell precursor ALL. New Indication Approved: March 29, 2018 Otiprio (ciprofloxacin) Treatment for: Tympanostomy Tube Placement Surgery; Acute Otitis Externa New Indication Approved: March 2, 2018 Source: Drugs.com Blinatumomab FDA expands approval of blincyto (blinatumomab) to treat minimal residual disease-positive B-Cell precursor acute lymphoblastic leukemia New Indication Approved: March 29, 2018 Information Collected and complied by: Md. Akbar Hossain Department of Pharmacy ASA University Bangladesh
7 New Current Drug pharma Approvals news 179 Current Pharma News Bowel Cancer: Low-calorie soft drinks could reduce recurrence Published: July 20, 2018 By Catharine Paddock PhD Consuming artificially sweetened soft drinks such as diet colas may be linked to a significantly lower risk of cancer return or death in patients with stage 3 colorectal cancers. Are essential oils safe for babies? Last reviewed Friday 20 July 2018 By Amanda Barrell Reviewed by Carissa Stephens, RN, CCRN, CPN There is some evidence for the benefits of essential oils, but very little research on how these oils may affect babies. It is crucial to note that the American Association of Naturopathic Physicians do not recommend using essential oils at all on babies younger than 3 months. How long does nicotine stay in your system? Last reviewed Thursday 19 July 2018 By Danielle Dresden Reviewed by Alan Carter, PharmD When people use tobacco products, some of the nicotine stays in their system after they quit smoking. Medical tests can detect nicotine in people's urine, blood, saliva, hair and nails. Nicotine is the addictive substance in tobacco, cigarettes and vapes or e- cigarettes. When someone smokes a cigarette, their body absorbs up to 90 percent of the nicotine. Traces of nicotine will linger long after individuals no longer feel the effects. After smoking a cigarette, nicotine and its by-products stay in a person s urine and saliva for 4 days and blood for up to 10 days. Eating dinner earlier could reduce cancer risk Published Thursday 19 July 2018 By Tim Newman According to a study that was conducted at the Barcelona Institute for Global Health in Spain, eating your final meal of the day too late can increase the risk of developing cancer. The relationship between food and cancer has been investigated to a great deal. For instance, regularly eating fresh vegetables has been shown to reduce cancer risk. Conversely, regularly eating red meat increases the risk of certain cancers. A recent study investigated potential links between meal timing and two common types of cancer: prostate cancer and breast cancer. Source: medicalnewstoday.com Non-dairy beverages like soy and almond milk may not be 'milk,' FDA suggests By Lindsey Ellefson, CNN Updated: July 19, 2018 (CNN)Got milk? If you're buying "milk" made with non-dairy products like almonds or oats, the US Food and Drug Administration isn't so sure you do. During a the Politico Pro Summit on Tuesday, FDA Commissioner Dr. Scott Gottlieb questioned whether the "standards of identity" applied to milk in the United States are being enforced correctly. The FDA describes milk as "the lacteal secretion, practically free from colostrum, obtained by the complete milking of one or more healthy cows." That definition doesn't leave room for vegan alternatives to call themselves "milk," though a number of products on the market do. Non-dairy milks, including soy, almond, rice and coconut milk are juices from nuts, seeds, grains and legumes that may be fortified with vitamins and minerals to deliver the equivalent nutrient profile and sometimes taste and consistency of cow's milk. Source: cnn.com/health The risk of having a heart attack while pregnant, giving birth, or during the two months after delivery, continues to increase for American women, a new study finds.
8 180 Current New Drug pharma Approvals news As published online July 18 in the Mayo Clinic Proceedings, the study, led by NYU School of Medicine researchers, found that the risk of suffering a heart attack among pregnant women rose 25 percent from 2002 to The researchers suggest that the trend among many women to have children later in life is one possible reason for the increase, as heart attack risk rises with age overall, and especially during pregnancy. More women, they say, are also obese and/or have diabetes, key risk factors for heart attack. Another factor that may explain the rising numbers is that myocardial infarcts, the technical name for heart attacks, are easier to detect than a decade ago, as tests for early protein markers of related heart cell damage have improved and become more widely available. Source: sciencedaily.com Information Collected and complied by: Md. Akbar Hossain Department of Pharmacy ASA University Bangladesh
9 New Herbal Drug and Approvals alternative medicine news 181 Herbal and Alternative Medicine News Green tea molecule could prevent heart attacks Date: May 31, 2018 Source: British Heart Foundation Scientists have discovered that a compound found in green tea, currently being studied for its ability to reduce amyloid plaques in the brain in Alzheimer's disease, also breaks up and dissolves potentially dangerous protein plaques found in the blood vessels. Nanoparticles derived from tea leaves destroy lung cancer cells: Quantum dots have great potential Date: May 21, 2018 Source: Swansea University Nanoparticles derived from tea leaves inhibit the growth of lung cancer cells, destroying up to 80 percent of them, new research has shown. The team made the discovery while they were testing out a new method of producing a type of nanoparticle called quantum dots. These are tiny particles which measure less than 10 nanometers. A human hair is 40,000 nanometers thick. Reishi mushroom powder is an effective treatment for mouth ulcers Published Date: 07/17/2018, By Edsel Cook The medicinal mushroom known as Reishi in Japan was the subject of a recent Chinese study on alternative treatments for recurrent oral ulceration (ROU). The results showed that freeze-dried reishi mushroom powder provided effective treatment for the most prevalent mouth ulcer disease in the world. ROU is considered an autoimmune disease. It is a frequent complication for acquired immune deficiency syndrome (AIDS) and other diseases that undermine the immune system. Asafoetida, a plant used in traditional folk medicines, found to show antitumor effects on breast cancer Published Date: 07/17/2018, By Ralph Flores Plants and herbs that have long been used in folk medicine may very well hold the key to treating modern-day diseases. In a study published in the Journal of Ayurveda and Integrative Medicine, researchers found that asafoetida, a plant used in traditional food and medicine, could potentially have anti-tumor and anti-metastasis effect against breast cancer. The study, led by researchers from Shahid Sadoughi University of Medical Sciences and Ahvaz Jundishapur University of Medical Sciences in Iran, looked at the effect of an oleo gum resin from asafoetida in mice induced with breast cancer. Herbal plants found to treat tuberculosis naturally Published Date: 07/17/2018, By Rhonda Johansson A major issue facing the medical community today is the rise of multidrug-resistant tuberculosis, which hampers current efforts to end the deadly disease globally. The World Health Organization (WHO) estimates that while the incidences of tuberculosis have been decreasing by around two percent each year, all effort must be made in exploring every option to treat it. This includes validating well-known traditional ethnomedicines. It was with this goal that researchers analyzed the extracts of crepe jasmine (Tabernaemontana coronaria), lemongrass (Cymbopogon citratus) and crepe ginger (Costus speciosus). These plant materials have been traditionally used as remedies for various symptoms of tuberculosis. Researchers evaluated the three plant extracts for their anti-tuberculosis activity. Part of their analysis included assessing which phytochemical compounds were the most active in influencing the growth kinetics and cellular integrity of a tubercle organism. Source: alternativemedicine.news Information Collected and complied by: Md. Akbar Hossain Department of Pharmacy ASA University Bangladesh
FDA Approval LIST. WellINFORMED
FDA Approval LIST Formulary management is one way to bring down drug costs, and deciding which medications to include on a formulary is part of this process. New drug releases are generally associated
More informationSeptember 2018 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to UCare (approved drug list). These changes are reviewed based
More information04 September 2017 Page 1 of 6
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationAnnual Flash Report (unaudited) Fiscal Year ended March 31, 2017
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationNew Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications
Q4 2017 Advair Diskus salmeterol Asthma, COPD inhaler Advair HFA salmeterol Asthma inhaler Airduo Respiclick salmeterol Asthma inhaler Alecensa alectinib Non-Small Cell Lung Cancer Genentech announced
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)
More informationAfinitor. Afinitor and Afinitor Disperz (everolimus) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 7 Last Review Date: June 22, 2017 Afinitor Description Afinitor and
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationChanges from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 4 Last Review Date: September 15, 2017 Lynparza Description Lynparza
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationMedication Guide Enbrel (en-brel) (etanercept)
Medication Guide Enbrel (en-brel) (etanercept) Read the Medication Guide that comes with Enbrel before you start using it and each time you get a refill. There may be new information. This Medication Guide
More informationAfinitor. Afinitor and Afinitor Disperz (everolimus) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 9 Last Review Date: June 22, 2018 Afinitor Description Afinitor and
More informationFigure 1. Comparison of Cancer Incidence Rates 1 of Individual Census Tracts with Louisiana, All Cancers Combined,
Figure. Comparison of Cancer Incidence Rates of Individual Census Tracts with Louisiana, All Cancers Combined, 006-04 The rate is statistically significantly lower than Louisiana The rate is not statistically
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationActemra (tocilizumab) CG-DRUG-81
Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationPegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440
This spreadsheet is updated monthly and enables self-audit of a medicines for All guidelines refer to adults unless indicated. No copyright is asserted on this Technology appraisal (TA) Titles are hyperlinks
More informationWhat should I ask my treatment team?
TREATMENT TRANSFORMED Child portrayed is not a real KYMRIAH patient. DISCUSSION GUIDE What should I ask my treatment team? Making treatment decisions for relapsed or refractory cancer can be hard. Asking
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 11 No 12, September 2017 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationIMMUNOTHERAPY FOR LUNG CANCER
IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Lung Cancer Basics... 2 Immunotherapy... 3 FDA Approved Immunotherapies...
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationHEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
More informationo Your healthcare provider should test you for TB before starting CIMZIA.
Medication Guide CIMZIA (CIM-zee-uh) (certolizumab pegol) lyophilized powder or solution for subcutaneous use Read the Medication Guide that comes with CIMZIA before you start using it, and before each
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationBLINCYTO can eliminate detectable traces of cancer 1
For people* with B-cell precursor ALL who are MRD+, 1 BLINCYTO can eliminate detectable traces of cancer 1 In a study of 86 adults with MRD+ B-cell precursor ALL, BLINCYTO removed detectable traces of
More informationPfizer Pipeline. August 9, 2012
Pfizer Pipeline August 9, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationContents Please refer to Medical Policy I-40 Pertuzumab (Perjeta) for additional information.
May 2018 In This Issue Coverage Guidelines Revised for Azacitidine (Vidaza)... 3 Coverage Guidelines Revised for Fulvestrant (Faslodex)... 4 Place of Service Revised for Total Hip and Total Knee Arthroplasty...
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More informationKEY INDICATORS OF NUTRITION RISK
NUTRITION TOOLS KEY INDICATORS OF Consumes fewer than 2 servings of fruit or fruit juice per day. Consumes fewer than 3 servings of vegetables per day. Food Choices Fruits and vegetables provide dietary
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationVectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:
What s New Medical Pharmaceutical Policy November 2017 Updates MBP 40.0 Orencia IV (abatacept)- New Indication Orencia IV (abatacept) will be considered medically necessary when all of the following criteria
More informationoffers the possibility of a longer life 1 BLINCYTO A guide for patients and caregivers
In a study of 405 adults with Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, 271 were treated with BLINCYTO and 134 with chemotherapy. The adults
More informationDeveloping a Oncology Treatment Resource for Claims-Based Research: Innovation with Medications
Developing a Oncology Treatment Resource for Claims-Based Research: Innovation with Medications Donna R. Rivera, PharmD., MSc. Scientific Project Officer and Pharmacist Surveillance Informatics Branch
More informationMerck Pipeline. November 1, 2017
Merck Pipeline November 1, 2017 Lead-in Language The chart below reflects the Company s research pipeline as of November 1, 2017. Candidates shown in Phase 3 include specific products and the date such
More informationUniversity Gynecologic Oncology Associates
University Gynecologic Oncology Associates Medical History Form Date: Name: Date of Birth: / / GYNE HISTORY Age of first period? If you no longer have periods, at what age did they stop? Are you pregnant
More informationWe re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications
We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Cone Health Disclosures Merck Pharmaceuticals Speaker s Bureau 1 Objectives
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
More informationWelcome to About Women by Women
Welcome to About Women by Women Today s Date New Patient Questionnaire Name: Birth Date: / / Home Phone: Address: Cell Phone: Work Phone: Occupation: Employer: Marital Status: Married Living w/ Partner
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationAdded, Removed or Changed. Date of Change. No Change
One mission: you s September 7, 2017 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationBiological Therapies for Cancer: Questions and Answers
Biological Therapies for Cancer: Questions and Answers Key Points Biological therapies use the body s immune system to fight cancer or to lessen the side effects that may be caused by some cancer treatments
More informationwhat vitamins are what vitamins are for
what vitamins are and what vitamins are for www.eurovit.eu page 1/23 Vitamins are essential for human body life. Vitamins are organic compounds that are needed in small quantities to sustain life. No vitamins
More informationNutrition and Cancer. Prof. Suhad Bahijri
Nutrition and Cancer Objectives 1. Discuss current knowledge regarding nutritional prevention of cancer 2. Discuss goals for the cancer patient 3. Explain how cancer treatment affects nutritional needs
More informationInvestor Update. Downloads. Services PDF. Basel, 15 May 2018
Investor Update Basel, 15 May 2018 FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (pjia), a rare form of juvenile arthritis Roche (SIX: RO,
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationNocdurna (desmopressin acetate) NEW PRODUCT SLIDESHOW
Nocdurna (desmopressin acetate) NEW PRODUCT SLIDESHOW Introduction Brand name: Nocdurna Generic name: Desmopressin acetate Pharmacological class: Vasopressin (synthetic) Strength and Formulation: 27.7mcg,
More informationHow much magnesium do I need?
NIH Office of Dietary Supplements Magnesium Fact Sheet for Consumers Table of Contents What is magnesium and what does it do? How much magnesium do I need? What foods provide magnesium? What kinds of magnesium
More informationReference ID:
MEDICATION GUIDE CLENPIQ (CLEN-pik) (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution Read and understand these Medication Guide instructions at least 2 days before your colonoscopy
More informationGenentech Statement on Counterfeit Drug Labeled as Avastin (bevacizumab) in the United States
Genentech Statement on Counterfeit Drug Labeled as Avastin (bevacizumab) in the United States SOUTH SAN FRANCISCO, Calif. February 14, 2012 Roche and Genentech have been informed that a counterfeit product,
More informationIntro to Vitamins, Minerals & Water
Intro to Vitamins, Minerals & Water 1. What is the main function of vitamins and minerals? To regulate body functions 2. What foods are a lot of the vitamins and minerals we need found in? Fruits and Vegetables
More informationin the form of carbohydrates, fats, proteins, vitamins, and minerals
BCS_G8_U1C02_J15 5/23/06 11:45 AM Page 64 2.2 The Digestive and Excretory Systems A healthy body requires nutrients from five groups: carbohydrates, proteins, fats, vitamins, and minerals. There are four
More informationClinical Policy: Everolimus (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63
Clinical Policy: (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63 Effective Date: 01/18 Last Review Date: Coding Implications Revision Log Description The intent of the criteria is to ensure
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationPATIENT HEALTH QUESTIONNAIRE Radiation Oncology
REVIEWED DATE / INITIALS Safety: Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: If YES, please list medication allergies: Do you have
More informationMerck Pipeline. August 1, 2018
Merck Pipeline August 1, 2018 Lead-in Language The chart below reflects the Company s research pipeline as of August 1, 2018. Candidates shown in Phase 3 include specific products and the date such candidate
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationPATIENT HEALTH QUESTIONNAIRE Radiation Oncology
REVIEWED DATE / INITIALS Safety: Yes No Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: Yes No If YES, please list medication allergies:
More informationMEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)
MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationThis information describes calcium supplements and how to take them.
PATIENT & CAREGIVER EDUCATION Calcium Supplements This information describes calcium supplements and how to take them. Calcium is a mineral that you need to build and maintain healthy bones. If you don
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationLecture 17: Vaccines (Therapeutic and Prophylactic Types)
Lecture 17: Vaccines (Therapeutic and Prophylactic Types) Therapeutic vaccines Bacillus Calmette Guerin (BCG; TheraCys) Very old agent initially developed as vaccine for MTB. Uses: Superficial bladder
More informationIntegrative Consult Patient Background Form
Let Us Know More - So We Can Help Thank you for choosing to schedule an integrative medicine consultation with UC Health. To help us meet your needs during your visit, please take some time to sit in a
More informationMS Society of Canada Recommendations on Vitamin D in MS 1
MS Society of Canada Recommendations on Vitamin D in MS Many people affected by MS have questions about vitamin D, and whether it can prevent MS or be used to help stop the disease from getting worse.
More informationR&D Pipeline (May 2010)
R&D Pipeline (May 2010) 1 Global development (1) Filed Stage in the Most Advanced Territory YM617 tamsulosin Alpha-1 receptor antagonist Lower urinary tract syndrome in male patients (June 2007) New indication
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More information3 generations of ADPKD. 1 long-awaited treatment.
3 generations of ADPKD. 1 long-awaited treatment. HOPE is finally here now that treatment is available for people with autosomal dominant polycystic kidney disease (ADPKD). JYNARQUE is proven to slow kidney
More informationAnswering the question- Why Should You Care What You Are Eating???
Answering the question- Why Should You Care What You Are Eating??? Never eat more than you can lift. - Miss Piggy Portion Distortion 6 Main Nutrients Vitamins Minerals Water Carbohydrates Protein Fat Keep
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
More informationThe Role of Obesity and Diabetes in Cancer JOEL RUSH MS RD CSO LD CNSC FAND UT M. D. ANDERSON CANCER CENTER HOUSTON TEXAS
The Role of Obesity and Diabetes in Cancer JOEL RUSH MS RD CSO LD CNSC FAND UT M. D. ANDERSON CANCER CENTER HOUSTON TEXAS Objectives Differentiate between modifiable cancer risk factors and non-modifiable
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 34 th Prioritization 1 st quarter 2018 General Information, efficacy and safety data Nicole Grössmann Sarah Wolf Please note: Within this document
More informationCarelirst.+.V Family of health care plans
Carelirst.+.V Family of health care plans CVS Caremark POLICY Document for ACTEMRA The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific
More informationInitial Consultation
Today s Date: Initial Consultation Thank you for choosing Apollo Health and Wellness. Please take your time to fill out this form. It will help us to concentrate on areas of your health that need attention
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationHealthy Mouth, Healthy You. The connection between oral and overall health
Healthy Mouth, Healthy You The connection between oral and overall health Your dental health is part of a bigger picture: whole-body wellness. Learn more about the relationship between your teeth, gums
More informationLIFE STYLE ASSESSMENT FORM. Name: Date: Age: Sex:
LIFE STYLE ASSESSMENT FORM Name: Date: Age: Sex: Please answer each of the following questions. If you require additional space, there s a blank Page at the end of the form. What is your purpose in coming
More informationSun Ancon total Enzymes
Sun Ancon total Enzymes Enzymes Enzymes regulate the normal processes of digestion, absorption, detoxification, blood circulation, balance our body PH and waste removal all essential to the very functions
More information